Helmholtz Health Partnering Event 2026

19 Nov 2026 | Berlin, Germany

Register
Register
Register

EBViously

Other

www.ebviously.comMunich, Germany
1 profile visit

About

EBViously is a spin-off from Helmholtz Munich, focused on developing next-generation vaccines using virus-like particle (VLP) platforms. The company brings together leading experts in Epstein–Barr virus research. Helmholtz Munich has secured over €12 million in funding from the German Center for Infection Research (DZIF) and the Helmholtz Validation Fund (HVF). EBViously has exclusively secured the relevant patent portfolio from Helmholtz Munich for further development and commercialization of the EBV vaccine program.

Social media

Areas of activity

Disease Area

Inflammation / Autoimmune DiseasesInfectious DiseasesNeurological Diseases

Technology

Other

Biomedical Research, Medicine, Human Health

Clinical Research, TrialsOther

Representatives

CEO

EBViously